Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028 - Visiongain Report

Tuesday, June 12, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, June 12, 2018 /PRNewswire/ --

Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis,

Eylea, Avastin, Visudyne

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne

- our new study reveals trends, R&D progress, and predicted revenues. Where is the Retinal disease therapeutic market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2028, assessing data, trends, opportunities and business prospects there.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

Discover how to stay ahead Our 171-page report provides 140 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disease market. See how to exploit the opportunities.

Forecasts from 2018-2028 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you find revenue forecasts to 2028 for the following submarkets: • Wet age-related macular degeneration (wAMD) • Dry AMD (dAMD) • Diabetic retinopathy (DR) • Other retinal diseases (grouped forecast)   Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those eye drug revenues? How will individual retinal medicines perform from 2018 to 2028 at world level? Our study forecasts revenues of four prominent brands: • Lucentis • Eylea • Avastin • Visudyne

Discover how high revenues can go. See what's happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries? You will discover individual revenue forecasts for 11 leading national markets from 2018-2028: • United States (US) • JapanGermany, France, the UK, Italy and Spain (EU5 group) • Brazil, Russia, India and China (BRIC countries).

Leading companies and the potential for market growth Our analysis forecasts that the world market for retinal drugs will reach $14.85bn in 2018. It will achieve strong revenue expansion from 2018 to 2028. Our report reveals how high sales will go over the next 10 years.   Research and development - assess innovation, trends and possibilities There you can also investigate R&D, appraising technological, clinical and commercial possibilities. In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others: • Combination therapies, including neovascularisation disrupters • Angiogenesis inhibition by blocking pericyte recruitment • Anti-inflammatory mechanisms (inc. corticosteroids) • Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways) • Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these: • Oligonucleotides and siRNA therapy • Anti-integrin oligopeptide treatment • Complement factor inhibition and serotonin modifiers • Angiotensin receptor blockers and converting enzyme inhibitors • Biosimilars and other follow-on biologicals and next generation therapeutics • Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne. Avoid missing out - get our report now.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/Report/2211/Global-Macular-Degeneration-(AMD)-and-Other-Retinal-Diseases-Drugs-Industry-and-Market-2018-2028

Companies Listed 

Abbott Acucela Pharmaceuticals Alcon Alimera Sciences Allegro Opthalmics Allergan Ampio Pharmaceuticals Ampio Pharmaceuticals Avalanche Biotechnologies Bayer Healthcare Bioeq GmbH Biophytis Biovail Corporation Bristol-Myers Squibb CalTech Cell Cure Neurosciences Ltd Centocor Chengdu Kanghong Chengdu Kanghong Biotech Clearside Biomedical CoMentis Daiichi Sankyo Diffusion Pharmaceuticals Eli Lilly ESBATech Eye Gate Pharmaceuticals ForSight Vision4 Gene Signal Genentech GlaxoSmithKline Hemera Biosciences iCo Therapeutics Icon Bioscience Iconic Therapeutics Janssen Pharmaceuticals Jiangsu T-mab BioPharma Kala Pharmaceuticals LPATH Lpath, Inc. MacuCLEAR Mateon Therapeutics Medical Need Merck Sharp & Dohme Mesoblast Mitsubishi Tanabe Pharma Molecular Partners MorphoSys Neuron Systems Neurotech Novartis Novo Nordisk Oakwood Laboratories Ocata Therapeutics (Advanced Cell Technology) OHR Pharmaceutical Ophthotech Corporation OpRegen (Biotime) Opthea Ora Bio Othera Pharmaceuticals Otsuka Pharmaceutical Oxford BioMedica Oxigene PanOptica Pfenex Pfizer pSivida Quark Regenerative Patch Technologies Regeneron/Bayer Regenxbio ReVision Therapeutics River Vision Development Roche RXi Pharmaceuticals Sanofi Santen Pharmaceutical SARcode Bioscience SciFluor Life Sciences Senju Pharmaceutical SGS Life Science Services Stealth BioTherapeutics StemCells Stemedica Cell Technologies SV Life Sciences Third Rock Ventures ThromboGenics Tyrogenex UCB Valeant Pharmaceuticals Vitreoretinal Technologies Xcovery Vision

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store